Dispensing and Discontinuation of Medications with Genetic Interactions in Real-World Data
Purpose: To evaluate frequency of clinically actionable drug-gene interactions and whether presence of genetic interactions was associated with time to medication discontinuation in a cohort of US Veterans with and without HIV. Methods: Pharmacogenomic interactions (PGx) were defined as Clinical Pharmacogenomics Implementation Consortium (CPIC) Level A interactions. Using this definition, we identified 20 most frequently dispensed medications with at least one interaction as defined by CPIC. We calculated percentage of people dispensed ≥1 CPIC level A medication. Among those recipients, we calculated the percentage of people with a CPIC level A interaction (CPIC A PGx) and compared time to discontinuation between those with/without CPIC A PGx using Bonferroni corrected Wilcoxon rank-sum tests. Results: Of 1,452 patients, 70% were Black, 6% Hispanic, 22% White, and 3% other with the mean age at 56 years. Of these, 98% (1,420/1452) had at least one CPIC A medication, including antiretrovirals, and immunosuppressants. Of those who were dispensed with CPIC A medication, 83% had CPIC A PGx. The clinical recommendations for these interactions varied from dose to medication change. Among individuals prescribed efavirenz, having a PGx was associated with shorter time to discontinuation and Tacrolimus was associated with longer time to discontinuation. The remaining 18 CPIC medications did not demonstrate a significant association with time to discontinuation. Conclusion: Many patients with CPIC A PGx are prescribed CPIC medications. We found no clear pattern of shorter time to discontinuation for those with a CPIC A PGx. Future work should explore the real-world impact of specific interactions.
Authors
- Amy C. Justice (ORCID: https://orcid.org/0000-0003-0139-5502)
- Christopher T. Rentsch (ORCID: https://orcid.org/0000-0002-1408-7907)
- Kathleen A. McGinnis (ORCID: https://orcid.org/0000-0003-4844-3372)
- Farah Kidwai‐Khan (ORCID: https://orcid.org/0000-0002-1913-0206)
- Xu Ke
Institutions
- Yale University (US)
- VA Connecticut Healthcare System (US)
- London School of Hygiene & Tropical Medicine (GB)
Publication Details
- Published
- 2026-11-16
- DOI
- https://doi.org/10.22541/authorea.15012298/v1
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- preprint